Please ensure Javascript is enabled for purposes of website accessibility

Why Catalyst Pharmaceuticals Stock Crashed in August

By George Budwell – Sep 8, 2020 at 11:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Catalyst can't seem to catch a break in the clinic these days.

What happened

Shares of the rare-disease drugmaker Catalyst Pharmaceuticals (CPRX 1.14%) fell by a staggering 23.7% during the month of August, according to data provided by S&P Global Market Intelligence. Catalyst's shares hit the skids last month following a negative late-stage readout for its flagship drug, Firdapse, as a treatment for muscle-specific kinase myasthenia gravis (also known as MuSK-positive myasthenia gravis). MuSK-positive myasthenia gravis is a debilitating neuromuscular disorder with few viable treatment options. 

Unfortunately, this latest failure is the drug's second major miss in the clinic in less than a year. In 2019, Firdapse also flopped in a late-stage trial for another neuromuscular disorder known as congenital myasthenic syndrome. Taken together, these two lost indications were worth upwards of $400 million in annual sales for Catalyst's one and only approved product. 

A businessman with a laptop folded over his head, while holding a sign that reads help in all capital letters.

Image source: Getty Images.

So what

Not that long ago, Wall Street and retail investors alike flocked to this small-cap biopharma stock in the hopes that Firdapse could one day achieve peak annual sales in the area of $700 million to $1 billion. With two of the drug's most lucrative indications now off the table, however, Catalyst's shares have seemingly lost a good bit of their luster. Underscoring this point, the drugmaker's shares have now fallen by close to 60% relative to their 52-week high. 

Now what

Can Catalyst bounce back? While it might be tempting to buy this beaten-down biotech stock after this rapid and rather sharp decline, it's probably a better idea to watch this story unfold from the safety of the sidelines. Firdapse's once-promising growth story hasn't exactly gone according to plan, after all. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Catalyst Pharmaceuticals, Inc. Stock Quote
Catalyst Pharmaceuticals, Inc.
CPRX
$12.85 (1.14%) $0.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
104%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.